Becton Dickinson gets FDA approval for third drug in its BD Simplist line


Becton, Dickinson (BDX +0.3%) subsidiary BD Rx says the FDA has approved a third drug to be offered in its new BD Simplist line of ready-to-administer prefilled generic injectables.

The third product to launch is Ondansetron Injection, an injectable antiemetic which is used to prevent postoperative nausea and vomiting.

The drug is currently on the FDA drug shortage list due to recent demand increases and supply issues faced by other manufacturers.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs